



Atty. Dkt. No. SALK 2270-5
(088802-5212)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: EVANS, et al.
Title: NOVEL STEROID-ACTIVATED
NUCLEAR RECEPTORS AND USES
THEREFOR
Appl. No.: 10/081,555
Filing Date: February 20, 2002
Examiner: Unknown
Art Unit: Unknown

<p align="center">CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.</p> <p><u>GERMAINE SARDA</u> (Printed Name)</p> <p><u><i>Germaine Sarda</i></u> (Signature)</p> <p><u>November 19, 2002</u> (Date of Deposit)</p>

AMENDMENT

Commissioner for Patents
Box Missing Parts
Washington, D.C. 20231

Sir:

In response to the Office communication dated September 20, 2002 (Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures), please consider the following amendments and remarks.

In the Specification

Please replace paragraphs [0061] and [0062] with the following amended paragraphs [0061] and [0062]. A marked-up version of these paragraphs, showing the changes made, is also provided herewith as Appendix A.

-- [0061] Examples of response elements suitable for use in practice of the invention methods can be selected from the following:

DR-3,4,5 = AGGTCANnAGGTCA, wherein n is 3, 4, or 5 (SEQ ID NOs: 44, 45 and 46);

β DR-3,4,5 = AGTTCANnTGAAC, wherein n is 3, 4 or 5 (SEQ ID NOs: 47, 48 and 22); and

IR-6 = TGAACnAGGTCA, wherein n is 6 (SEQ ID NO: 23), and the like.

[0062] Those of skill in the art will recognize that any combination of nucleotides can be used to make up the 3, 4, 5, or 6 nucleotide space between the repeated half sites (*i.e.*, Nn in SEQ ID NOs: 44, 45, 46, 22 or 23). --

Sequence Listing

Applicants respectfully submit a computer readable form (CRF) and a paper copy of the sequence listing herewith. A statement to support filing and submission in accordance with 37 C.F.R. 1.821-1.825 is also enclosed herewith.